BERKELEY, CA (UroToday.com) - In this presentation, Dr. Christopher Pieczonka of Associated Medical Professionals discusses the treatment experience, in a large urology group setting, of patients receiving immunotherapy for metastatic castration-resistant prostate cancer (mCRPC).
Christopher Pieczonka, MD graduated from the SUNY Buffalo School of Medicine in 1997. He then completed his surgical and urologic training at SUNY at Buffalo Consortium Program in 2003. He is board certified by the American Board of Urology and is an active member of the American Urological Association. Dr. Pieczonka also has been co-author of publications in the Journal of Urology.
Dr. Pieczonka is currently the executive vice-president of the Physician Teamster Alliance of CNY Local #1149 and has a specialty interest in the treatment of advanced prostate cancer. His patients were the first to be treated with Provenge® (sipuleucel-T), a new immunotherapy for metastatic prostate cancer.